Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
Titled “Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions,” the patent covers a proprietary method for deriving MSCs from pluripotent stem cells, to which Cynata Therapeutics with commercial rights in Japan through 2031. [Read more…]